EGFR and non-small cell lung carcinoma: This study conducts the first meta-analysis specifically focusing on the EGFR L858R subtype to systematically evaluate ICI efficacy (monotherapy vs. combinations) in the post-TKI setting.<h4>Methods</h4>We systematically searched PubMed, EMBASE, Cochrane, and Web of Science (up to January 1, 2026) for studies on ICI-treated EGFR-mutated NSCLC.